Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 3/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040923 | 1.00 | SMYD3 (0.33) | SMYD3CD38PDK2KDM4ECYP11B1 | |
| SCHEMBL14759114 | 0.84 | EPHX1 (0.36) | CD38PDK2KDM4ECYP11B1CYP11B2 | |
| SCHEMBL14759093 | 0.82 | EPHX1 (0.39) | CD38SMN1; SMN2ALDH1A1 | |
| SCHEMBL15724863 | 0.80 | SMYD3 (0.35) | SMYD3 | |
| SCHEMBL77050 | 0.79 | CD38 (0.34) | CD38PDK2KDM4ECYP11B1CYP11B2 | |
| SCHEMBL18502887 | 0.78 | CHRM3 (0.40) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18502850 | 0.78 | CD38 (0.38) | CD38PDK2CYP11B1CYP11B2 | |
| SCHEMBL13223467 | 0.78 | CD38 (0.38) | CD38PDK2CYP11B1CYP11B2 | |
| SCHEMBL8560336 | 0.78 | ITGB3 (0.38) | SMYD3 | |
| SCHEMBL8415991 | 0.78 | ITGB3 (0.38) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | SMYD3 911/4885CD38 2856/4885PDK2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.